Business: Idiverging paths, difficult clhoices

Drug Discovery World

Volumn 14, Issue 1, 2012, Pages 9-16

  Arlington, Steve ^a   Davies, Nick ^b  

^a Global Pharmaceutical and Life Sciences Advisory Services   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMMERCIAL PHENOMENA; DEMOGRAPHY; DRUG INDUSTRY; MARKETING; MEDICAL TECHNOLOGY; MEDICINE; PHARMACEUTICAL ENGINEERING; PHARMACY; SCIENTIFIC LITERATURE;

EID: 84874174003     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. US National Human Genome Research Institute (2012). DNA Sequencing Costs. Available at http://www.genome.gov/seque ncingcosts/.
2. Herper, Matthew (10 January 2012). Biotech Firms Battle Over Same Day Genomes. Forbes. Available at http://www.forbes.com/sites/rn atthewherper/2012/01/10/biot ech-firms-battle-over-sameday-genomes//.
3. Voight, Benjamin F et al (17 May 2012). Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet. Available at http://www.thelancet.com/jour nals/lancet/article/PIISO 140- 6736%2812%2960312-2/fulltext
4. Fisher, Shannon (April 2012). Big Pharma + Big Pharma = Collaborative Fight to Cancer. PharmaShare. Available at http://www.pharmashare.com/big- pharma-bigpharma-collaborativeapproach-fight-cancer.
5. Ten Pharmaceutical Companies Unite to Accelerate Development of New Medicines (19 September 2012). PR Newswire. Available at http://www.prnewswire. com/news-releases/tenpharmaceutical-companiesunite-to-acceleratedevelopment-of- newmedicines-170329346.html.
6. European Medicines Agency (27 July 2006). Guideline On Clinical Trials In Small Populations.
7. O' Riordan, Michael (4 November 2011). FDA approves rivaroxaban for stroke prevention in AF patients, theheart.org. Available at http://www.theheart.org/article/l3042l3.do.
8. PhRMA (2012). Medicines in Development: Vaccines.]
9. Gray, Richard (8 April 2012). "Universal" cancer vaccine developed. The Telegraph. Available at http://www.telegraph.co.uk/sci ence/sciencenews/9191848/Universalcancer-vaccine-developed.html.
10. Barnatt, Christopher (17 June 2012). Bioprinting. Explaining The Future.com. Available at http://www.explainingthefuture.com/bioprinting.html.
11. Clinical trials news: January 2012 update. EuroStem Cell. Available at http://www.euro stemcell.org/story/clinicaltrials-news-january-2012-update.
12. Boseley, Sarah (4 June 2012). Stem cell scientists take hope from first human trials but see long road ahead. The Guardian. Available at http://www.guardian. co.uk/scie nce/2012/jun/04/stem-cell-firsthuman-trials.
13. Pammolli, Fabio et al (June 2011). The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery 10:428-438.
14. Arrowsmith, John (May 2011). Trial watch: Phase II fialures: 2008-2010. Nature Reviews Drug Discovery 10:1.
15. Arrowsmith, John (February 2011). Trial watch: Phase III and submission failures: 2007-2010. Nature Reviews Drug Discovery 10:1.
16. Arrowsmith, John (January 2012). A decade of change. Nature Reviews Drug Discovery II: 17-18.
17. Arrowsmith, John (February 2011). Trial watch: Phase III and submission failures: 2007-2010. Nature Reviews Drug Discovery 10:1.
18. Adams, Ben (10 February 2012). Value destruction: pharma has only itself to blame. InPharm. Available at http://www.inpharm.com/news/171302/value- destructionpharma-has-only-itself-blame.
19. Booth, Bruce (19 April 2012). Culture as a culprit of the Pharma R&D crisis. Forbes. Available at http://www.forbes.com/sites/br ucebooth/2012/04/19/ cultureas-a-culprit-of-the-pharma-rdcrisis/.